Harmony Gold Mining reports 61% operating profit surge but output decline and copper capex weigh on HMY stock
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
Read More 5 minute read Healthcare Industry News Tharimmune (NASDAQ: THAR) resale filing unlocks 0.326m shares — Is dilution risk back on the table? Tharimmune’s 0.326 M-share resale filing raises liquidity and dilution questions for THAR investors. Learn what it means for stock sentiment and outlook. byPallavi MadhirajuOctober 18, 2025